



Reimagining pet medications®

Presentation


Problem

- Daily dosing of pets requires commitment and can be stressful to the pet and challenging to pet parents.
- There is a lack of medications formulated specifically for pets and human medications are often prescribed which requires the breaking up of pills.
- This results in imprecise dosing and lack of adherence to prescription.
- Diminishes the likelihood of a positive outcome from the course of treatment.



Solution

- Lifescient is reformulating medications currently being prescribed to pets for chronic conditions into subdermal long-acting injectables (LAI).
- LAIs will offer freedom from the demands of daily dosing and guarantee prescription compliance.
- LAIs will enhance pet comfort, especially important during times when requiring relief from a chronic condition or end of life pain and illness.




About LAIs

- Subdermal long-acting injectables have been approved by the FDA for use in humans to treat opioid addiction.
- Lifescent is leveraging this drug delivery platform and adapting it for veterinary medicine by incorporating a biodegradable polymer that is regarded as safe by the FDA.
- A single LAI placed under the skin similar to a microchip placement will deliver controlled release of medicine from days to months at a time and then safely absorbed by the body.




LAIs are Differentiated Products

- Product pipeline consists of reformulated medications previously approved for human and/or animal use.
- Our “First-in-Class” products have the potential for marketing exclusivity.
- Our LAIs technology can be formulated to treat a variety of conditions/diseases across multiple species of animals.
- Our subdermal LAIs have the potential to be safer than daily chronic dosing.



Advantages of LAIs Over Daily Oral Dosing


- Prescription compliance guaranteed.
- Reduce side-effects because drug remains within therapeutic window.
- Greater bioavailability due to drug not passing through GI tract (a cost savings).



Our First Product, LS-001

- Indicated for the control of pain associated with bone cancer in dogs which is a Minor Use in a Major Species (MUMS).
- Has the potential for addressing pain associated with other types of cancer, surgery, as well as chronic pain.
- Veterinarians we surveyed have indicated an overwhelming likelihood of prescribing our analgesic LAI.

Very Likely to Prescribe Our LAIs




Accomplishments

- FDA granted request to open an Investigational New Animal Drug file.
- Sponsor fee waivers granted under the MUMS provision for our first product will save the company more than \$1,000,000 in development costs.
- Established technical feasibility for several medications.
- Developed several prototypes of subdermal long-acting injectable medications.




Product Pipeline - Analgesia




* MUMS: FDA Minor Use and Minor Species Act

Portfolio Expansion



Veterinary Medicine: A Growing and Resilient Market

Global Companion Animal Pharmaceuticals
Market Size, Share, and COVID-19 Impact
Analysis; Source: SphericalInsights




Pet Stocks are recession-resistant (Packaged Facts)
“...greater spending on pets by millennials and pet ownership by Gen Z are some of the factors fueling the growth of the pet therapeutics market.” Kristen Peck, CEO of Zoetis – August 2022

- Global companion animal pharmaceuticals market was valued at \$15.60 Billion in 2022 and is expected to reach \$27.16 Billion by 2032¹.
- Veterinary pain management market was valued at USD 1.2 billion in 2020 and it is expected to reach \$1.9 billion in 2026².

1: Spherical Insights and Consulting.
2: Mordor Intelligence.

Go To Market Strategy



"We primarily sell our companion animal products to veterinarians or to third-party veterinary distributors that typically then sell our products to veterinarians, and in each case, veterinarians then typically sell our products to pet owners...Our two largest customers, both distributors, represented approximately 14% and 9%, respectively, of our revenue for the year ended December 31, 2022, and no other customer represented more than 8% of our revenue for the same period.." - Zoetis, 10K, 2022

Our Team


We have a team experienced in the pharmaceutical industry, veterinary industry, business development and marketing. Our team is focused on developing LAIs to meet the current demand and future needs.



Kamalesh Rao
Founder & CEO



Renee Sera
Chief Admin. Officer



Dr. Mari A. Delaney
Clinical Veterinary Advisor



Dr. Craig Miller
Scientific Advisor



Daniele Campos
Business Consultant



Amy Berlin
Project Manager

LAI Development For Pets

A Win/Win Venture

- **Pet Health:** Guaranteed prescription compliance leading to superior clinical results.
 - **Pet Families:** Greater comfort to pets and peace of mind to pet families.
 - **Veterinarians:** Confidence in knowing their pet patients will receive improved care and incentivized by new revenue sources.
 - **Environmental Benefit:** Green manufacturing process, minimizes use of rubber gloves for LAIs that replace topicals, and eliminates leftover drugs which otherwise would get dumped into the ecosystem.
 - **Investors:** Benefiting financially from a technology that will have a positive and meaningful impact.
-

Thank You



Reimagining pet medications®

Website:

www.lifescient.com

Email:

kamalesh@lifescient.com

Forward Looking Statements | 2024

This presentation, and any supplement to this presentation include “forward-looking statements”. To the extent that the information presented in this presentation discusses financial projections, information, or expectations about our business plans, results of operations, products, or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward looking statements can be identified using words such as “intends”, “anticipates”, “believes”, “estimates”, “projects”, “forecasts”, “expects”, “plans” and “proposes”. Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements.

This summary only highlights selected information. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.